Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

8 evidence topics · 9 sources

Guideline table of bladder-sparing options for carcinoma in situ with or without papillary disease
CompoundStudy designnFollow-up (months)CR at 3 months (%)CR at 6 months (%)CR at 12 months (%)Adverse events
Nadofaragene firadenovec“Phase III Cis Cohort”“103”“19.7”“53.4”“40.8”“24.3”“G3 4%”
Cretostimogene grenadenorepvec (CG0070)“Phase II”“45”Not reportedNot reported“58 CIS”; “50 CIS+P”Not reported“G1-2 82.5% G ≥ 3 4.5%”
Nogapendekin alfa inbakicept plus BCG“Phase II/III QUILT 3032 CA”“82”“23.9”“55.0”“56.0”“45.0”“G1-2 86% G ≥ 3 23%”
TAR-200“Phase II b SunRISe-1 C2”“81”“20.2”“78.8”“58.8”“45.9”“Any G 83.5% G ≥ 3 12.9%”
Pembrolizumab“Phase II Cohort A KEYNOTE-057”“96”“36.4”“41.0”Not reported“18.7”“G1-2 53.0% G ≥ 3 13%”
Nadofaragene firadenovec: indication, dosing, and efficacy in prescribing information